BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27806325)

  • 1. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
    Emadi A; Jun SA; Tsukamoto T; Fathi AT; Minden MD; Dang CV
    Exp Hematol; 2014 Apr; 42(4):247-51. PubMed ID: 24333121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
    Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
    Masamha CP; LaFontaine P
    J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a novel glutaminase inhibitor.
    Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
    FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
    Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
    Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
    Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP
    Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
    Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
    J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
    Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW
    J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
    Stalnecker CA; Erickson JW; Cerione RA
    J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
    Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
    J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glutamine metabolism slows soft tissue sarcoma growth.
    Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC
    Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography.
    Milano SK; Huang Q; Nguyen TT; Ramachandran S; Finke A; Kriksunov I; Schuller DJ; Szebenyi DM; Arenholz E; McDermott LA; Sukumar N; Cerione RA; Katt WP
    J Biol Chem; 2022 Feb; 298(2):101535. PubMed ID: 34954143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of novel glutaminase inhibitors.
    McDermott LA; Iyer P; Vernetti L; Rimer S; Sun J; Boby M; Yang T; Fioravanti M; O'Neill J; Wang L; Drakes D; Katt W; Huang Q; Cerione R
    Bioorg Med Chem; 2016 Apr; 24(8):1819-39. PubMed ID: 26988803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.